{"id":"tdm-based-infliximab-intravenous-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including tuberculosis, fungal, and opportunistic)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Increased liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infliximab is a chimeric monoclonal antibody that specifically targets and blocks TNF-alpha, a key pro-inflammatory cytokine. By neutralizing TNF-alpha, it suppresses the inflammatory cascade and reduces immune-mediated tissue damage. TDM-based (therapeutic drug monitoring) dosing optimizes infliximab exposure to maintain therapeutic levels while minimizing immunogenicity and adverse effects.","oneSentence":"Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha, reducing inflammatory responses in autoimmune and inflammatory diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:26.870Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT06051253","phase":"PHASE4","title":"TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2023-11-01","conditions":"Crohn Disease, Infliximab, Perianal Fistula Due to Crohn's Disease","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TDM-based infliximab (CT-P13, RemsimaTM) intravenous therapy"],"phase":"marketed","status":"active","brandName":"TDM-based infliximab intravenous therapy","genericName":"TDM-based infliximab intravenous therapy","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha, reducing inflammatory responses in autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}